Cash Flow Statement

Altimmune (ALT) Capital Expenditures (2010 - 2026)

Altimmune (ALT) reported Capital Expenditures of $21000.0 for Q1 2026, up 2000.0% on a QoQ basis from $1000.0 in Q4 2025.

Altimmune (ALT) has 15 years of Capital Expenditures data on file, last reported at $21000.0 in Q1 2026.

  • Quarterly Capital Expenditures changed N/A year-over-year to $21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22000.0 (changed N/A YoY) and the FY2025 annual result came in at $11000.0, changed N/A from the prior year.
  • Capital Expenditures grew to $21000.0 in Q1 2026 per ALT's latest filing, from $1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $60000.0 in Q3 2022 and bottomed at -$4000.0 in Q2 2023.
  • The 4-year median for Capital Expenditures is $20000.0 (2022), against an average of $24375.0.
  • Peak annual rise in Capital Expenditures reached 466.67% in 2023, while the deepest fall reached 121.05% in 2023.
  • Tracing ALT's Capital Expenditures over 4 years: stood at $38000.0 in 2022, then sank by 110.53% to -$4000.0 in 2023, then soared by 125.0% to $1000.0 in 2025, then surged by 2000.0% to $21000.0 in 2026.
  • Per Business Quant, the three latest ALT Capital Expenditures figures stand at $21000.0 (Q1 2026), $1000.0 (Q4 2025), and -$4000.0 (Q2 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 21.83 Mn
10 Altimmune 379.61 Mn 379.61 Mn - 21,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 21,000.00
Mar 31, 2026 21,000.00
Dec 31, 2025 1,000.00
Dec 31, 2025 1,000.00
Jun 30, 2023 -4,000.00
Jun 30, 2023 -4,000.00
Mar 31, 2023 51,000.00
Mar 31, 2023 51,000.00
Dec 31, 2022 38,000.00
Dec 31, 2022 38,000.00
Sep 30, 2022 60,000.00
Sep 30, 2022 60,000.00
Jun 30, 2022 19,000.00
Jun 30, 2022 19,000.00
Mar 31, 2022 9,000.00
Mar 31, 2022 9,000.00
Dec 31, 2021 147,000.00
Dec 31, 2021 147,000.00
Sep 30, 2021 70,000.00
Sep 30, 2021 70,000.00
Jun 30, 2021 7.69 Mn
Jun 30, 2021 7.69 Mn
Mar 31, 2021 4.21 Mn
Mar 31, 2021 4.21 Mn
Dec 31, 2020 103,628.00
Dec 31, 2020 103,628.00
Sep 30, 2020 59,728.00
Sep 30, 2020 59,728.00
Jun 30, 2020 22,470.00
Jun 30, 2020 22,470.00
Mar 31, 2020 18,131.00
Mar 31, 2020 18,131.00
Sep 30, 2019 1.00
Sep 30, 2019 1.00
Mar 31, 2019 1,226.00
Mar 31, 2019 1,226.00
Dec 31, 2018 7,053.00
Dec 31, 2018 7,053.00
Sep 30, 2018 156,708.00
Sep 30, 2018 156,708.00
Jun 30, 2018 159,011.00
Jun 30, 2018 159,011.00
Mar 31, 2018 652,635.00
Mar 31, 2018 652,635.00
Dec 31, 2017 238,535.00
Dec 31, 2017 238,535.00
Sep 30, 2017 5,951.00
Sep 30, 2017 5,951.00
Jun 30, 2017 44,316.00
Jun 30, 2017 44,316.00
Mar 31, 2017 39,582.00
Mar 31, 2017 39,582.00
Dec 31, 2016 11,915.00
Dec 31, 2016 11,915.00
Sep 30, 2016 100,516.00
Sep 30, 2016 100,516.00
Jun 30, 2016 12,374.00
Jun 30, 2016 12,374.00
Mar 31, 2016 150.00
Mar 31, 2016 150.00
Dec 31, 2015 18,230.00
Dec 31, 2015 18,230.00
Sep 30, 2015 12,000.00
Sep 30, 2015 12,000.00
Jun 30, 2015 20,925.00
Jun 30, 2015 20,925.00
Mar 31, 2015 35,352.00
Mar 31, 2015 35,352.00
Sep 30, 2014 13,042.00
Sep 30, 2014 13,042.00
Jun 30, 2014 42,177.00
Jun 30, 2014 42,177.00
Mar 31, 2014 37,050.00
Mar 31, 2014 37,050.00
Sep 30, 2013 13,998.00
Sep 30, 2013 13,998.00
Jun 30, 2013 45,113.00
Jun 30, 2013 45,113.00
Mar 31, 2013 25,468.00
Mar 31, 2013 25,468.00
Sep 30, 2011 41,075.00
Sep 30, 2011 41,075.00
Dec 31, 2010 50,002.00
Dec 31, 2010 50,002.00
Sep 30, 2010 -10,835.00
Sep 30, 2010 -10,835.00